Over 15 years, advanced cutaneous squamous cell carcinoma has moved from limited chemotherapy and EGFR inhibition to checkpoint blockade. Dr. Chandra and Dr. Patel trace how the 2018 approvals restructured treatment sequencing and the timing of oncologic involvement.
As systemic therapy enters earlier in the disease course, coordinated care becomes essential. Dr. Carr and Dr. Patel examine the communication infrastructure, such as tumor boards, referral pathways, and cross-specialty literacy, that distinguishes academic centers from community practice.
